(Q37881948)

24 August 2017

1 reference

title

Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential (English)

1 reference

24 August 2017

0 references

1 reference

2

Harald Hampel

1 reference

24 August 2017

3

Richard Dodel

1 reference

24 August 2017

Carmen Noelker

1

1 reference

24 August 2017

publication date

1 April 2011

1 reference

Molecular Diagnosis and Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

15

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

83-102

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256398

24 August 2017

exact match

0 references

cites work

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Microvascular injury and blood-brain barrier leakage in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Serum creatinine levels correlate with plasma amyloid Beta protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Autoantibodies to amyloid-beta and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Altered amyloid protein processing in platelets of patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Platelet APP isoform ratios correlate with declining cognition in AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Alzheimer disease-related abnormalities of amyloid beta precursor protein isoforms in the platelet: the brain's delegate in the periphery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

The involvement of lipid rafts in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Lipid metabolism in cognitive decline and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Serum lipoprotein levels, statin use, and cognitive function in older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Expression of apolipoprotein E during nerve degeneration and regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Statement on Use of Apolipoprotein E Testing for Alzheimer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Mitochondrial involvement in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Lipid peroxidation and free radical scavengers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Vitamin C and Vitamin E for Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Alzheimer's disease and oxygen radicals: new insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Inflammation and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Inflammation and therapeutic vaccination in CNS diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Biomarkers of Alzheimer disease in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

A serum protein-based algorithm for the detection of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Inflammatory proteins in plasma and the risk of dementia: the rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Circulating cytokines in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Brain infarction and the clinical expression of Alzheimer disease. The Nun Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Proteome-based plasma biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Neuroprotection in Parkinson's disease: clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Biological fluid biomarkers in neurodegenerative parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Immunity to growth factor receptor-bound protein 10, a signal transduction molecule, inhibits the growth of breast cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Oxidative stress in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Decreased platelet glutamate uptake and genetic risk factors in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Platelet monoamine oxidase B activity in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Increased expression of dopamine receptors on lymphocytes in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Lewy body diseases and multiple system atrophy as alpha-synucleinopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Alpha-synuclein in Lewy body disease and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Physiological and pathological properties of alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Characterization of a novel protein regulated during the critical period for song learning in the zebra finch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Genetics of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

alpha-Synuclein locus triplication causes Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Red blood cells are the major source of alpha-synuclein in blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Expression of alpha-synuclein, the precursor of non-amyloid beta component of Alzheimer's disease amyloid, in human cerebral blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Plasma alpha-synuclein is decreased in subjects with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Sweat function in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Mapping of a gene for Parkinson's disease to chromosome 4q21-q23

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Genetic variability in the SNCA gene influences α-synuclein levels in the blood and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Parkinson patient fibroblasts show increased alpha-synuclein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Autoantibodies to alpha-synuclein in inherited Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

The neuromelanin of human substantia nigra: physiological and pathogenic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Multiple sclerosis: immune system molecule expression in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Reactive nitrogen intermediates in human neuropathology: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Peripheral inflammatory biomarkers and risk of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Circulating interleukin-10 and interleukin-12 in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Metabolomics: current technologies and future trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Metabolomics: a global biochemical approach to the study of central nervous system diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Metabolomics in the study of aging and caloric restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Metabolomics tools for identifying biomarkers for neuropsychiatric diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Metabolic profiling of serum using Ultra Performance Liquid Chromatography and the LTQ-Orbitrap mass spectrometry system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Metabolomic analysis and signatures in motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Mass spectrometry-based metabolomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Metabolomic profiling to develop blood biomarkers for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Genomic and proteomic biomarkers for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Modulation of in vivo HSP70 chaperone activity by Hip and Bag-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Abnormal serum concentrations of proteins in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Methylation status and neurodegenerative markers in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

The ceruloplasmin and hydrogen peroxide system induces alpha-synuclein aggregation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

21 January 2018

Brain iron metabolism

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Clinical and pathological correlates of apolipoprotein E ?4 in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256398

Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease.

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FBF03256398

21 January 2018

12 December 2020

Activated human microglia produce the excitotoxin quinolinic acid

1 reference

12 December 2020

alpha-Synuclein shares physical and functional homology with 14-3-3 proteins

1 reference

12 December 2020

Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease

1 reference

12 December 2020

Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.

1 reference

12 December 2020

Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease

1 reference

12 December 2020

Serum inflammatory biomarkers in Parkinson's disease.

1 reference

12 December 2020

S100B and NSE serum levels in patients with Parkinson's disease

1 reference

12 December 2020

Differential Level of Platelet Amyloid beta Precursor Protein Isoforms: An Early Marker for Alzheimer Disease

1 reference

12 December 2020

1 reference

12 December 2020

Induction of Prostanoid Biosynthesis by Bacterial Lipopolysaccharide and Isoproterenol in Rat Microglial Cultures

1 reference

12 December 2020

Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease.

1 reference

12 December 2020

Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia

1 reference

12 December 2020

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals

1 reference

12 December 2020

Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain

1 reference

12 December 2020

Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer's disease (DAT): lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT.

1 reference

12 December 2020

Immunocytochemical investigations on the presence of neuron-specific antibodies in the CSF of Parkinson's disease cases

1 reference

12 December 2020

Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression

1 reference

12 December 2020

Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease

1 reference

12 December 2020

Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group

1 reference

12 December 2020

1 reference

12 December 2020

Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease

1 reference

12 December 2020

Parkinson's disease: an autoimmune process

1 reference

12 December 2020

Selective Reductions in Plasma A 1-42 in Healthy Elderly Subjects During Longitudinal Follow-Up: A Preliminary Report

1 reference

12 December 2020

Activated microglia mediate neuronal cell injury via a nitric oxide mechanism

1 reference

12 December 2020

Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity

1 reference

12 December 2020

A correlation study between serum adenosine deaminase activities and peripheral lymphocyte subsets in Parkinson's disease

1 reference

12 December 2020

Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response

1 reference

12 December 2020

Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease

1 reference

12 December 2020

Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood.

1 reference

12 December 2020

Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease

1 reference

12 December 2020

Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients

1 reference

12 December 2020

Serum cytokine levels in patients with Alzheimer's disease

1 reference

12 December 2020

The amyloid precursor protein of Alzheimer's disease is released by human platelets.

1 reference

12 December 2020

Platelet alpha- and gamma-synucleins in Parkinson's disease and normal control subjects

1 reference

12 December 2020

Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease

1 reference

12 December 2020

Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta.

1 reference

12 December 2020

Integrative Profiling of Metabolites and Proteins

1 reference

12 December 2020

Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor rece

1 reference

12 December 2020

Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk

1 reference

12 December 2020

Secretion of DJ-1 into the serum of patients with Parkinson's disease

1 reference

12 December 2020

gamma delta+ T cells are increased in patients with Parkinson's disease

1 reference

12 December 2020

Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease

1 reference

12 December 2020

Genetic testing for Alzheimer's disease.

1 reference

12 December 2020

Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants

1 reference

12 December 2020

Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis.

1 reference

12 December 2020

alpha-Synuclein is phosphorylated in synucleinopathy lesions

1 reference

12 December 2020

Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease

1 reference

12 December 2020

Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease

1 reference

12 December 2020

Presymptomatic detection of Parkinson's disease

1 reference

12 December 2020

Microglial and astroglial reactions to inflammatory lesions of experimental autoimmune encephalomyelitis in the rat central nervous system

1 reference

12 December 2020

APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis

1 reference

12 December 2020

Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques

1 reference

12 December 2020

Abnormalities of the electron transport chain in idiopathic Parkinson's disease

1 reference

12 December 2020

Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo.

1 reference

12 December 2020

Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain

1 reference

12 December 2020

Oxidative stress indicators are elevated in de novo Parkinson's disease patients.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256398

1 reference

24 August 2017

1 reference